1. Home
  2. HLF vs ORKA Comparison

HLF vs ORKA Comparison

Compare HLF & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Herbalife Ltd.

HLF

Herbalife Ltd.

HOLD

Current Price

$14.23

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Logo Oruka Therapeutics Inc.

ORKA

Oruka Therapeutics Inc.

HOLD

Current Price

$27.81

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HLF
ORKA
Founded
1980
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Other Pharmaceuticals
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.5B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
HLF
ORKA
Price
$14.23
$27.81
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
10
Target Price
$15.50
$48.20
AVG Volume (30 Days)
2.1M
719.0K
Earning Date
02-18-2026
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
264.95
N/A
EPS
3.11
N/A
Revenue
$4,961,900,000.00
N/A
Revenue This Year
$1.20
N/A
Revenue Next Year
$3.52
N/A
P/E Ratio
$4.53
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.04
$5.49
52 Week High
$15.17
$32.64

Technical Indicators

Market Signals
Indicator
HLF
ORKA
Relative Strength Index (RSI) 63.32 44.15
Support Level $12.68 $25.23
Resistance Level $14.21 $32.64
Average True Range (ATR) 0.55 2.15
MACD -0.13 -0.55
Stochastic Oscillator 77.73 34.55

Price Performance

Historical Comparison
HLF
ORKA

About HLF Herbalife Ltd.

Herbalife Ltd is an international nutrition company that provides health and wellness products to consumers in 95 markets, which consist of countries and territories, through their direct-selling business model. Companies' products are weight management, targeted nutrition, Energy, Sports and Fitness, Outer Nutrition and Literature, Promotional, and Other. Weight management generates the majority of revenue from products like Meal replacements, protein shakes, drink mixes, weight loss enhancers, and healthy snacks. Geographically, the main segments are North America, Latin America, EMEA, Asia Pacific regions, and China.

About ORKA Oruka Therapeutics Inc.

Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.

Share on Social Networks: